⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for metastatic colon adenocarcinoma

Every month we try and update this database with for metastatic colon adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerNCT03992456
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Unresectable Co...
Unresectable Co...
Unresectable Re...
Panitumumab
Quality-of-Life...
Questionnaire A...
Regorafenib
Trifluridine an...
18 Years - Academic and Community Cancer Research United
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE TrialNCT03765736
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Genetic Testing
18 Years - Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerNCT04362839
Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationNCT05308446
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IV Colon ...
Stage IV Rectal...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - National Cancer Institute (NCI)
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerNCT04362839
Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerNCT04017650
BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal CancerNCT05130060
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Micr...
Metastatic Micr...
Metastatic Rect...
Microsatellite ...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Colorectal Canc...
Trifluridine an...
18 Years - Mayo Clinic
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerNCT04017650
BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerNCT04044430
Metastatic Colo...
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Binimetinib
Encorafenib
Nivolumab
Questionnaire A...
18 Years - University of California, San Francisco
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerNCT04017650
BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE TrialNCT03765736
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Genetic Testing
18 Years - Academic and Community Cancer Research United
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyNCT04109924
Advanced Colore...
Metastatic Colo...
Metastatic Rect...
Recurrent Colon...
Recurrent Color...
Recurrent Recta...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IV Colon ...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Unresectable Co...
Unresectable Co...
Unresectable Re...
Irinotecan
Bevacizumab
Trifluridine an...
18 Years - Roswell Park Cancer Institute
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationNCT05308446
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IV Colon ...
Stage IV Rectal...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - National Cancer Institute (NCI)
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyNCT05356897
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Trastuzumab
Trifluridine an...
Tucatinib
18 Years - Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerNCT04362839
Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerNCT03592641
Colorectal Carc...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Savolitinib
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: